June 29, 2017

Vigilant Biosciences Commences Studies of Oral Cancer Test

Vigilant Biosciences Inc, Fort Lauderdale, Fla, has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its premarket regulatory submission to FDA. Vigilant Biosciences’ initial clinical study is designed to validate performance and evaluate implementation of the OncAlert rapid…

Read

June 29, 2017

Fort Lauderdale biotech firm gets federal grant for oral cancer study

Fort Lauderdale-based Vigilant Biosciences, which has developed dental and lab toolkits for early detection of oral cancer, has been awarded part of a multi-million dollar grant for a study from the National Institutes of Health. The five-year study will enroll 300 mouth and throat cancer…

Read

June 2, 2017

Tests May Detect Oral Cancer Earlier

Oral and throat cancers can be life-threatening, and their frequency seems to be increasing. Now, two tests that are simple, painless and noninvasive can often detect them at very early stages when they can often be treated successfully. Both were developed here in South Florida.…

Read

May 12, 2017

Number To Know…1,000

Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test. Source: Medtech Insight

Read

May 12, 2017

Oral Cancer Tests

The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating…

Read